Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1225720rdf:typepubmed:Citationlld:pubmed
pubmed-article:1225720lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:1225720lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:1225720lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:1225720lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:1225720pubmed:issue6lld:pubmed
pubmed-article:1225720pubmed:dateCreated1976-8-2lld:pubmed
pubmed-article:1225720pubmed:abstractTextAntitumor activity of 1-carbamoyl derivatives of 5-fluorouracil was tested in L-1210 system by oral administration with two reference compounds, 5-fluorouracil and tetrahydrofuryl-5-fluorouracil (FT-207). The compounds tested were methyl-, ethyl-, isopropyl-, phenyl-, and cyclohexyl-carbamoyl-5-fluorouracil, and the therapeutic ratios (ILSmax/ILS30) of these compounds were 1.9, 2.2, 2.3, 1.0, and greater than 3.3, respectively, those of the two reference compounds being 1.7 and 1.0. Cyclohexylcarbamoyl-5-fluorouracil was the most effective of these compounds.lld:pubmed
pubmed-article:1225720pubmed:languageenglld:pubmed
pubmed-article:1225720pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1225720pubmed:citationSubsetIMlld:pubmed
pubmed-article:1225720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1225720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1225720pubmed:statusMEDLINElld:pubmed
pubmed-article:1225720pubmed:monthDeclld:pubmed
pubmed-article:1225720pubmed:issn0016-450Xlld:pubmed
pubmed-article:1225720pubmed:authorpubmed-author:YoshidaMMlld:pubmed
pubmed-article:1225720pubmed:authorpubmed-author:HoshiAAlld:pubmed
pubmed-article:1225720pubmed:authorpubmed-author:KuretaniKKlld:pubmed
pubmed-article:1225720pubmed:authorpubmed-author:IigoMMlld:pubmed
pubmed-article:1225720pubmed:issnTypePrintlld:pubmed
pubmed-article:1225720pubmed:volume66lld:pubmed
pubmed-article:1225720pubmed:ownerNLMlld:pubmed
pubmed-article:1225720pubmed:authorsCompleteYlld:pubmed
pubmed-article:1225720pubmed:pagination673-4lld:pubmed
pubmed-article:1225720pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:1225720pubmed:meshHeadingpubmed-meshheading:1225720-...lld:pubmed
pubmed-article:1225720pubmed:meshHeadingpubmed-meshheading:1225720-...lld:pubmed
pubmed-article:1225720pubmed:meshHeadingpubmed-meshheading:1225720-...lld:pubmed
pubmed-article:1225720pubmed:meshHeadingpubmed-meshheading:1225720-...lld:pubmed
pubmed-article:1225720pubmed:meshHeadingpubmed-meshheading:1225720-...lld:pubmed
pubmed-article:1225720pubmed:meshHeadingpubmed-meshheading:1225720-...lld:pubmed
pubmed-article:1225720pubmed:year1975lld:pubmed
pubmed-article:1225720pubmed:articleTitleAntitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administration.lld:pubmed
pubmed-article:1225720pubmed:publicationTypeJournal Articlelld:pubmed